内科

目的探讨使用Embosphere微球多次动脉化疗栓塞治疗中晚期肝癌患者的临床效果及安全性。方法选取2017年1月至2019年2月我院收治的中晚期肝癌患者120例为研究对象，随机分成研究组与对照组，每组60例。对照组患者给予常规化疗药物+碘化油进行动脉化疗栓塞治疗，研究组患者给予常规化疗药物+Embosphere微球进行动脉化疗栓塞治疗。比较两组患者治疗前后的肝功能；比较两组患者的临床疗效及治疗期间的不良反应发生情况。结果末次治疗1个月后，两组患者的总胆红素（TBil）水平明显升高，直接胆红素（DBil）、谷丙转氨酶（ALT）、谷草转氨酶（AST）水平均明显降低，差异有统计学意义（P＜0.05）；但在治疗前后，两组患者的TBil、DBil、ALT、AST水平比较，差异均无统计学意义（P＞0.05）；对患者进行CT或MRI检查的结果显示，研究组患者的治疗总有效率（66.67%）明显高于对照组（41.67%），差异有统计学意义（P＜0.05）。治疗期间，两组患者的不良反应发生情况比较差异无统计学意义（P＞0.05），两组患者均未发生肝肾功能衰竭、消化道出血及肝破裂等严重不良反应。结论使用Embosphere微球作为栓塞剂治疗中晚期肝癌患者的远期效果优于以碘化油作为栓塞剂治疗，治疗安全性高，值得推广使用。

ObjectiveTo explore the clinical effect and safety of multiple arterial chemoembolization by Embosphere in patients with intermediate-advanced liver cancer. MethodsA total of 120 intermediate-advanced liver cancer patients admitted to our hospital from January 2017 to February 2019 were selected as the research objects, and were randomly divided into study group and control group, with 60 cases in each group. Patients in the control group were administered conventional chemotherapy medicine + iodized oil for arterial chemoembolization, whereas the study group was given conventional chemotherapy medicine + Embosphere for arterial chemoembolization. The liver function, clinical efficacy, and the occurrence of adverse reactions during treatment were compared between the two groups. ResultsOne month after the last treatment, the total bilirubin(TBil) level increased significantly in both group, whereas the levels of direct bilirubin(DBil), 3.alanine transaminase(ALT), and aspartate aminotransferase(AST) decreased significantly in both groups, with statistically significant differences (P＜0.05); however, there were no statistically significant differences in TBil, DBil, ALT, AST levels between the two groups before and after treatment (P＞0.05). The results of CT or MRI examinations on patients showed that the total effective rate of treatment in the study group (66.67%) was significantly higher than that in the control group (41.67%), and the differences were statistically significant (P＜0.05). During treatment, there was no statistically significant difference in the occurrence of adverse reactions between the two groups (P＞0.05). No serious adverse reactions as for liver and kidney failure, gastrointestinal bleeding and liver rupture occurred in both groups. ConclusionThe long-term effect of using Embosphere as an embolization agent in the treatment of patients with intermediate-advanced liver cancer is superior to that of using iodized oil as an embolization agent, with higher safety of treatment, and it is worthy of promotion.